Murphy & Mullick Capital Management Corp Buys New Shares in Thermo Fisher Scientific Inc. (NYSE:TMO)

Murphy & Mullick Capital Management Corp purchased a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 363 shares of the medical research company’s stock, valued at approximately $189,000.

Several other institutional investors have also recently made changes to their positions in the stock. Legacy Investment Solutions LLC acquired a new position in Thermo Fisher Scientific during the third quarter worth $26,000. Barrett & Company Inc. bought a new position in Thermo Fisher Scientific in the 4th quarter valued at about $28,000. FPC Investment Advisory Inc. acquired a new position in Thermo Fisher Scientific during the 4th quarter valued at about $28,000. Missouri Trust & Investment Co purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth approximately $29,000. Finally, Pillar Financial Advisors LLC bought a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $29,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $175,677.00. Following the sale, the executive vice president now owns 16,363 shares of the company’s stock, valued at $9,582,009.17. This trade represents a 1.80 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Stephen Williamson sold 9,825 shares of the company’s stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the transaction, the chief financial officer now directly owns 27,296 shares of the company’s stock, valued at approximately $15,984,264.64. This trade represents a 26.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 23,900 shares of company stock valued at $13,106,062. Insiders own 0.34% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently commented on TMO. Royal Bank of Canada set a $693.00 price target on Thermo Fisher Scientific in a research report on Friday, January 31st. Citigroup cut their price target on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Raymond James reissued an “outperform” rating and set a $667.00 target price (up previously from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday, February 3rd. Scotiabank increased their price target on Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a “sector perform” rating in a research report on Monday, February 3rd. Finally, StockNews.com raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Tuesday, January 14th. Four equities research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $653.23.

Thermo Fisher Scientific Trading Down 0.2 %

Shares of Thermo Fisher Scientific stock opened at $513.40 on Thursday. The company has a 50 day simple moving average of $543.80 and a two-hundred day simple moving average of $553.93. The firm has a market cap of $193.68 billion, a PE ratio of 31.06, a PEG ratio of 2.99 and a beta of 0.79. Thermo Fisher Scientific Inc. has a 1 year low of $493.30 and a 1 year high of $627.88. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, beating analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.34%. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, March 14th. Thermo Fisher Scientific’s payout ratio is presently 10.41%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.